The Health Canada license confirms that the Axonics product meets all of the Canadian Medical Devices Regulations, Section 36, for Active Implantable Medical Devices and enables Axonics to market its r-SNM System throughout Canada. Axonics previously received ethics committee approval from the University of Toronto to treat patients in Canada as part of the Company’s post-market clinical follow-up study and anticipates treating patients in Canada in the first quarter of 2017.